VARIOVISC® based multi-drug combination therapy for management of OA knee related pain showed significant decreasement in VAS pain from baseline at 3 and 6 months follow-up in a preliminary study. 62 patients (25 females and 37 males; age mean 50.9 +-1.04) diagnosed with medial tibio-femoral bilateral symptomatic knee OA (Kellgren-Lawrence grade II and III), as assessed by X-rays taken 2-3 months before the study, were divided into three groups receiving VARIOVISC ® alone, VARIOVISC® and Diclofenac and VARIOVISC ® and Clasteon® (Clodronate). No serious adverse events were observed. All three groups using VARIOVISC ® showed significant decreasement in VAS pain from baseline at 3 and 6 months follow-up.